These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 28326642)

  • 1. Neprilysin inhibition in heart failure: mechanisms and substrates beyond modulating natriuretic peptides.
    D'Elia E; Iacovoni A; Vaduganathan M; Lorini FL; Perlini S; Senni M
    Eur J Heart Fail; 2017 Jun; 19(6):710-717. PubMed ID: 28326642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neprilysin and Natriuretic Peptide Regulation in Heart Failure.
    Bayes-Genis A; Morant-Talamante N; Lupón J
    Curr Heart Fail Rep; 2016 Aug; 13(4):151-7. PubMed ID: 27260315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current role of neprilysin inhibitors in hypertension and heart failure.
    von Lueder TG; Atar D; Krum H
    Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic options of Angiotensin Receptor Neprilysin inhibitors (ARNis) in chronic heart failure with reduced ejection fraction: Beyond RAAS and sympathetic nervous system inhibition.
    Volterrani M; Iellamo F; Senni M; Piepoli MF
    Int J Cardiol; 2017 Jan; 226():132-135. PubMed ID: 27184730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin Receptor-Neprilysin Inhibitor (ARNI) and Cardiac Arrhythmias.
    Sutanto H; Dobrev D; Heijman J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.
    Prenner SB; Shah SJ; Yancy CW
    Curr Atheroscler Rep; 2016 Aug; 18(8):48. PubMed ID: 27324636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin Receptor-Neprilysin Inhibitors and the Natriuretic Peptide Axis.
    Vasquez N; Carter S; Grodin JL
    Curr Heart Fail Rep; 2020 Jun; 17(3):67-76. PubMed ID: 32394149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic Progress and Knowledge Basis on the Natriuretic Peptide System in Heart Failure.
    Fu S; Chang Z; Luo L; Deng J
    Curr Top Med Chem; 2019; 19(20):1850-1866. PubMed ID: 31448711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ARNi: A Novel Approach to Counteract Cardiovascular Diseases.
    Volpe M; Rubattu S; Battistoni A
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond.
    Singh JS; Lang CC
    Vasc Health Risk Manag; 2015; 11():283-95. PubMed ID: 26082640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Novel perspectives in the therapy of heart failure: target--the system of natriuretic peptide degradation].
    Tereshchenko SN; Dzhaiani NA
    Kardiologiia; 2014; 54(10):72-7. PubMed ID: 25675724
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin receptor--neprilysin inhibiton (ARNI)--a novel therapeutic concept for management of hypertension and heart failure.
    Kjeldsen SE; Hedner T; Narkiewicz K; Oparil S
    Blood Press; 2012 Dec; 21(6):329-30. PubMed ID: 23210746
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuroendocrine activation as a target of modern chronic heart failure pharmacotherapy.
    Dobrek Ł; Thor P
    Acta Pol Pharm; 2011; 68(3):307-16. PubMed ID: 21648184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of RAAS-natriuretic peptides in the treatment of HF: Old guys and newcomers.
    Mollace V; Gliozzi M; Capuano A; Rossi F
    Int J Cardiol; 2017 Jan; 226():126-131. PubMed ID: 27075034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neprilysin Inhibitors: Filling a Gap in Heart Failure Management, Albeit Amidst Controversy and at a Significant Cost.
    Manolis AS; Manolis TA; Manolis AA; Melita H
    Am J Cardiovasc Drugs; 2019 Feb; 19(1):21-36. PubMed ID: 29926350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [ARNI, new abbreviation for a new class of treatment of heart failure].
    Karimzadeh S; Mustafić H; Stampfli Andres T
    Rev Med Suisse; 2017 Mar; 13(552):496-499. PubMed ID: 28714615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F; Lang CC; Struthers AD
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of neprilysin inhibitor combinations in hypertension: insights from hypertension and heart failure trials.
    Bavishi C; Messerli FH; Kadosh B; Ruilope LM; Kario K
    Eur Heart J; 2015 Aug; 36(30):1967-73. PubMed ID: 25898846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin-Aldosterone-Neprilysin Axis: Identification of Its Distinctive Role in the Pathogenesis of the Three Phenotypes of Heart Failure in People With Obesity.
    Packer M
    Circulation; 2018 Apr; 137(15):1614-1631. PubMed ID: 29632154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The natriuretic peptides system in the pathophysiology of heart failure: from molecular basis to treatment.
    Volpe M; Carnovali M; Mastromarino V
    Clin Sci (Lond); 2016 Jan; 130(2):57-77. PubMed ID: 26637405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.